Regenerative med-tech Tissue Regenix Group PLC (LON:TRX) is on the hunt for a new chief executive after Antony Odell stepped down.
Odell had been in the role since 2008 and will be replaced temporarily by non-executive chairman, John Samuel, who will step into an executive role until a new CEO is found.
READ: Tissue Regenix sees revenues double in ‘transformational’ first half
Tissue Regenix has pioneered a cell washing technology that allows grafts and replacement implants without rejection and most recently acquired Texas-based rival Cellright, which uses a similar technique for bone grafts.
Samuel said the integration of CellRight continues as planned and current trading remains in line with management expectations.
READ: Tissue Regenix confirms US$30mln acquisition of bone graft specialist Cellright
He thanked Odell for his dedication and commitment since he was appointed.
“During his tenure the company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight. “